Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.55 |
| ▸ | BID | P55957 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341368 | 0.87 | ALDH1A1 (0.58) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL4614435 | 0.87 | LIPG (0.44) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL10599587 | 0.87 | LIPG (0.50) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL11444088 | 0.85 | LIPG (0.56) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL5346786 | 0.85 | LIPG (0.56) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL5509741 | 0.85 | CYSLTR2 (0.56) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL10533245 | 0.85 | CYSLTR2 (0.56) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL8086397 | 0.85 | CYSLTR2 (0.56) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL8086516 | 0.85 | CYSLTR2 (0.56) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL9559902 | 0.85 | CYSLTR2 (0.56) | LIPGBIDMCL1BCL2L1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| EP-1546115-A2 | SUBSTITUTED PYRIMIDINES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004029204-A2 | SUBSTITUTED PYRIMIDINES | MERCK & CO., INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | CNR1, CNR2, MAG | LIPG 1084/4885BID 61/4885MCL1 602/4885 |
| US-20050245554-A1 | Substituted pyrimidines | CNR1, CNR2, GPR119 | LIPG 1086/4885BID 248/4885MCL1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.